Docs comfy with ePromotion, and many prefer it, says study

Share this article:
Sixty-seven percent of physicians had a positive attitude toward electronic promotional activities, up from 62% a year ago, according to an SDI study.

Additionally, 73% of the physicians surveyed for SDI's ePromotion Annual Study 2008 said pharma's electronic promotional activities (or ePromotion) were equal or superior to traditional face-to-face encounters.

“Through ePromotion, physicians have more time to review product information and review disease state information at their own convenience – at night time or on the weekends,” said Heather Alba, senior manager, promotional audits at SDI.

Other findings from the report include:
  • Sixty-nine percent of the physicians surveyed participated in ePromotional activities in the evening, outside of office hours. 
  • In 2008, the average amount of time spent by a physician on a single ePromotion activity was 18 minutes. 
  • Physicians ranked Merck as the leader in terms of the best ePromotion activities, followed by Pfizer and AstraZeneca respectively. 
The study, which included feedback from approximately 1,000 physicians across 14 specialties, defined ePromotion in three categories: virtual details (promotions without live communication); video details (live online promotion or telephone-assisted internet browsing); and virtual events (seminars, CME and KOL events, web conferences and group discussions).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...